sunitinib

Known as: 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, sunitinib [Chemical/Ingredient], 5-(5-fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 
An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1974-2017
020040060019742017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
BACKGROUND The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in… (More)
  • table 1
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND Hypertension (HTN) is an on-target effect of the vascular endothelial growth factor pathway inhibitor, sunitinib. We… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Immune dysfunction reported in renal cell carcinoma (RCC) patients may contribute to tumor progression. Myeloid-derived… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Herein we report that the VEGFR/PDGFR kinase inhibitor sunitinib/SU11248 can accelerate metastatic tumor growth and decrease… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Immune dysfunction is well documented in renal cell carcinoma (RCC) patients and likely contributes to tumor evasion… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • table 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Most gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor alpha (PDGFRA… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
CONTEXT Current treatment options for metastatic renal cell carcinoma (RCC) are limited and there is a need to identify novel and… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?